Autoimmune specialist Zenas BioPharma has posted a win for its lead candidate, obexelimab, from a mid-stage study in relapsing multiple sclerosis (RMS). During the Phase II MoonStone study ...
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...
Rick Blum is meticulous about planning, ordering, and taking the medication he is prescribed to slow the progression of multiple sclerosis, a chronic and incurable neurological disorder that has ...
Columnist Desiree Lama finds herself having to argue that a medicine that she has been taking for migraines for years is still needed.
Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...
Living with multiple sclerosis (MS) often means managing a mix of symptoms that affect daily life, including fatigue, mobility challenges, pain, and changes in strength and endurance. Body weight can ...
Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...
As of 2022, there were 15 oral and injectable MS drugs across seven types of "classes," or groups of medication that work in similar ways. These treatments are all pricey, usually costing $5,000 to ...
Hosted on MSN
Multiple sclerosis medication gap: Study finds women less likely than men to receive drugs
Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results